Povetacicept
Protein / enzyme therapeutic
Evidence outlook · regulatory review
IgA Nephropathy: application under FDA review, decision date 2026-11-30
FDA accepts povetacicept BLA for accelerated approval in IgAN (2026-06-01). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.
Also in development:Primary Membranous Nephropathy · Phase 2/3Myasthenia Gravis · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
RAINIER NCT06564142 · IgA Nephropathy Registry: NCT06564142 | 3 | Change From Baseline in 24-hour Urine Protein to Creatinine Ratio (uPCR) at Week 36 (From Baseline at Week 36); Total Estimated Glomerular Filtration Rate (eGFR) Slope Through Week 104 (From Baseline Through Week 104) 2028-01-30 | In progress: results expected 30 Jan 2028 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (1)
What this study did
Phase 1/2 (2)
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
Other BAFF / APRIL drugs
Telitacicept, aritinercept. Compare all 3 BAFF / APRIL drugs
2 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for IgA Nephropathy: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Povetacicept: this drug | Phase 3 | Protein / enzyme therapeutic | BAFF / APRIL | not yet graded | No reviewed efficacy summary in this indication | |
| Atacicept | Approved | Protein / enzyme therapeutic | BLyS/APRIL (B-cell activating factor/a proliferation-inducing ligand) | Partial signal | Featured results are non-efficacy only in this race | |
| Atrasentan (Vanrafia) | Approved | Small molecule | Endothelin A receptor | Partial signal | NCT04573478: Primary (interim, first 270 patients): 24-hour UPCR change at week 36, atrasentan -38.1% vs placebo -3.1%; between-group difference -36.1 percentage points (95% CI -44.6 to -26.4), P<0.001 | |
| Budesonide (targeted-Release) (TARPEYO / Nefecon) | Approved | Small molecule | Glucocorticoid receptor | Reliable signal | No reviewed efficacy summary in this indication | |
| Iptacopan (Fabhalta) | Approved | Small molecule | Complement Factor B | Partial signal | NCT04578834: Final analysis: annualized total eGFR slope over 24 months, iptacopan -3.10 vs placebo -6.12 mL/min/1.73 m2 per year; difference 3.02 (95% CI 2.02 to 4.01), adjusted P<0.001. Interim (month 9): 24-hour UPCR 38.3% lower with iptacopan (95% CI 26.0 to 48.6), P<0.001. Both primaries met. | |
| Ravulizumab (Ultomiris) | Approved | Monoclonal antibody | Complement C5 | Partial signal | NCT06291376: Primary 1, change in 24-hour UPCR at week 34 (prespecified interim analysis), ravulizumab vs placebo: the sponsor reports a statistically significant and clinically meaningful reduction, met; figures not yet published. Primary 2, change in eGFR at week 106: not yet reported; the trial is ongoing. | |
| Sparsentan (Filspari) | Approved | Small molecule | Angiotensin II receptor type 1 (AT1R) + Endothelin receptor type A (ETA) | Partial signal | Featured results are non-efficacy only in this race | |
| Felzartamab | Phase 3 | Monoclonal antibody | CD38 | not yet graded | No reviewed efficacy summary in this indication | |
| JADE101 | Phase 3 | Monoclonal antibody | APRIL (A Proliferation-Inducing Ligand, TNFSF13) | not yet graded | No reviewed efficacy summary in this indication | |
| Mezagitamab | Phase 3 | Monoclonal antibody | CD38 | not yet graded | No reviewed efficacy summary in this indication | |
| Sefaxersen | Phase 3 | RNA / oligonucleotide | Complement factor B (CFB) | Partial signal | NCT05797610: Prespecified interim analysis: statistically significant reduction in proteinuria (24-hour UPCR) vs placebo at week 37 (2026-09-23). | |
| Telitacicept | Phase 3 | Protein / enzyme therapeutic | BAFF / APRIL | not yet graded | No reviewed efficacy summary in this indication | |
| Zigakibart | Phase 3 | Monoclonal antibody | APRIL (A Proliferation-Inducing Ligand, TNFSF13) | not yet graded | No reviewed efficacy summary in this indication | |
| Ebribafusp Alfa | Phase 2 | Protein / enzyme therapeutic | C3d / Factor H | not yet graded | No reviewed efficacy summary in this indication | |
| Aritinercept | Phase 1/2(overall) | Protein / enzyme therapeutic | BAFF / APRIL | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| SCTC21C | Phase 1/2 | Biologic (subtype unspecified) | CD38 | not yet graded | No reviewed efficacy summary in this indication | |
| ARO-CFB | Phase 1 | RNA / oligonucleotide | Complement factor B (CFB) mRNA | not yet graded | No reviewed efficacy summary in this indication | |
| Opemalirsen | Phase 1(overall) | RNA / oligonucleotide | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Povetacicept to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
December 2027 (1)
What to watch
2028 (2)
2029 (3)
March 2029 (1)
What to watch
June 2029 (1)
What to watch
December 2029 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent